Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials
| Autor: | Francesca Arenare, Giuseppe Mancia, Guido Grassi, Raffaella Dell'Oro, Fosca Quarti Trevano |
|---|---|
| Přispěvatelé: | Grassi, G, Arenare, F, QUARTI TREVANO, F, Dell'Oro, R, Mancia, G |
| Rok vydání: | 2007 |
| Předmět: |
Nephrology
Blood pressure control medicine.medical_specialty Blood Pressure law.invention Randomized controlled trial Risk Factors law Internal medicine Internal Medicine Humans Medicine Intensive care medicine Stroke Antihypertensive Agents Secondary prevention Clinical Trials as Topic End point business.industry Risk Factor medicine.disease Primary Prevention Clinical trial Antihypertensive Agent Blood pressure Hypertension Physical therapy business |
| Zdroj: | Current Hypertension Reports. 9:299-304 |
| ISSN: | 1534-3111 1522-6417 |
| Popis: | High blood pressure represents one of the leading risk factors for the development of stroke and its recurrence. This explains why blood pressure control is a major objective of antihypertensive treatment, both in primary and secondary prevention of this cerebrovascular disease. This paper reviews the evidence provided by randomized clinical trials on the favorable effects exerted by blood pressure reduction on this end point. Emphasis is given to the results of recently published clinical trials documenting that drugs acting on the renin-angiotensin system may exert cerebrovascular protective effects additive to the ones associated with blood pressure reduction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink